Health researchers concerned about pause for public health communications
Staff members at agencies inside HHS, including officials at the Food and Drug Administration, Centers for Disease Control ...
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed success
MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
EHS Today43m
Hold My Beer, Red Dye No. 3 and Younger Cancer Patients: What I’m Reading This Week
There is a direct, well-established link between alcohol consumption and cancer risk for at least seven types of cancer ...
Clarity Pharmaceuticals: Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to ...
pulmonologyadvisor4h
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
STAT4h
New abortion pill shows promise — and potential political peril
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. STAT is ...
Scientific American6h
What’s in ZYN, the FDA-Authorized Nicotine Pouch? Is It Harmful?
ZYN, the popular brand of flavored nicotine pouches, recently earned FDA authorization for reducing smoking, but some ...
Peninsula biotech company sues insurance company to cover patients' injuries in clinical trials
A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...
Smoking and drinking less, young adults on LI support nicotine limits and alcohol warning labels
"I'm hoping the increased education makes a difference," said Nicholas Gallo, 26, of Deer Park, who called his generation ...
Exelixis's SWOT analysis: cabozantinib strength, pipeline potential drive stock
Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on developing and commercializing novel therapies for difficult-to-treat cancers, has demonstrated resilience and growth potential in ...
Trump's freeze on health agency communications leads to cancellation of scientific meetings
The Trump administration’s freeze on communications from U.S. health agencies is leading to another disruption: the abrupt cancellation of scientific meetings. The move covers a swath of health ...
What to know about red dye 3 being banned from foods
The U.S. Food and Drug Administration banned red dye No. 3 from foods. That was first announced on Jan. 15, 2025. This decision by federal regulators comes nearly 35 years after the dye was banned in ...